The bacteriophages and their gene products as antimicrobial agents;Los bacteriófagos y sus productos genicos como agentes antimicrobianos

Revista Espanola de Quimioterapia

Volumn 15, Issue 4, 2002, Pages 306-312

  Garcia E ^a   López, Rubens ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Antibiotic resistance; Bacteriophages; Phage therapy

Indexed keywords

ANTIINFECTIVE AGENT; GENE PRODUCT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIOPHAGE; EASTERN EUROPE; NONHUMAN; REVIEW; VIRUS ISOLATION;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; FORECASTING; HUMANS;

EID: 0036998585     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. D'Hérelle, F. Sur un microbe invisible antagoniste des bacilles dysentériques. Compt Rend Acad Sci (Paris) 1917; 165: 373-375.
2. Twort, F.W. An investigation on the nature of ultramicroscopic viruses. Lancet 1915; ii: 1241-1243.
3. Hankin, M.E. L'action bactericide des eaux de la Jumna et du Gange sur la microbe du choléra. Ann Inst Pasteur 1896; 10: 511-523.
4. Payne, R.J.H., Jansen, V.A.A. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 2001; 208: 37-48.
5. Sulakvelidze, A., Alavidze, Z., Morris Jr., J.G. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649-659.
6. Sulakvelidze, A., Morris, J.G. Bacteriophages as therapeutic agents. Ann Med 2001; 33: 507-509.
7. Summers, W.C. Bacteriophage therapy. Annu Rev Microbiol 2001; 55: 437-451.
8. Duckworth, D.H., Gulig, P.A. Bacteriophages: Potential treatment for bacterial infections. BioDrugs 2002; 16: 57-62.
9. Meselson, M., Stahl, F.W. Replication of DNA in Escherichia coli. Proc Natl Acad Sci USA 1958; 44: 671-676.
10. Avery, O.T., McLeod, C.M., McCarty, M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a deoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 1944; 79: 137-158.
11. Cairns, J., Stent, G., Watson, J. Phage and origins of molecular biology. Cold Spring Harbor Lab. Press, CSH, Long Island, New York, 1966.
12. Eaton, M.D., Bayne-Jones, S. Bacteriophage therapy. Review of the principles and results of the use of bacteriophage in the treatment of infections. J Am Med Assoc 1934; 103: 1769-1776, 1847-1853, 1934-1939.
13. Krueger, A.P., Scribner, E.J. Bacteriophage therapy: II. The bacteriophage. Its nature and its therapeutic use. J Am Med Assoc 1941; 116: 2160-2167, 269-2277.
14. Luria, S.E., Delbrück, M., Anderson, TF. Electron microscope studies of bacterial viruses. J Bacterial 1943; 46: 57-77.
15. Geier, M.R., Frigg, M.E., Merril, C.R. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 1973; 246: 221-222.
16. Smith, H.W., Huggins, M.B. Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. J Gen Microbiol 1982; 128: 307-318.
17. Smith, H.W., Huggins, M.B., Shaw, K.M. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophage. J Gen Microbiol 1987; 133: 1111-1126.
18. Levin, B.R., Bull, J.J. Phage therapy revisited: The population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Naturalist 1996; 147: 881-898.
19. Slopek, S., Weber-Dabrowska, B., Dabrowski, M., KucharewiczKrukowska, A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz) 1987; 35: 569-583.
20. Carlton, R.M. Phage therapy: Past history and future prospects. Arch Immunol Ther Exp (Warsz) 1999; 47: 267-274.
21. Merril, C.R., Biswas, B., Carlton, R. y cols. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA 1996; 93: 3188-3192.
22. Barrow, P.A., Soothill, J.S. Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential. Trends Microbial 1997; 5: 268-271.
23. Kucharewicz-Krukowska, A., Slopek, S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 5: 553-561.
24. Kudva, I.T., Jelacic, S., Tarr, P.I., Youderian, P., Hovde, C.J. Biocontrol of Escherichia coli 0157 with 0157-specific bacteriophages. Appl Environ Microbiol 1999; 65: 3767-3773.
25. Biswas, B., Adhya, S., Washart, P. y cols. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002; 70: 204-210.
26. Düring, K., Porsch, P., Fladung, M., Lörz, H. Transgenic potato plants resistant to the phytopathogenic bacterium Erwinia carotovora. Plant J 1993; 3: 587-598.
27. Nelson, D., Loomis, L., Fischetti, V.A. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001; 98: 4107-4112.
28. Loeffler, J.M., Nelson, D., Fischetti, V.A. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294: 2170-2172.
29. Sheehan, M.M., García, J.L., López, R., García, P. The lytic enzime of the pneumococcal phage Dp-1: A chimeric lysin of intergeneric origin. Mol Microbiol 1997; 25: 717-725.
30. Frenkel, D., Solomon, B, Filamentous phage as vector-mediated anti-body delivery to the brain. Proc Natl Acad Sci USA 2002; 99: 5675-5679.
31. Strój, L., Weber-Dabrowska, B., Partyka, K., Mulczyk, M., Wójcik, M. Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn. Neurol Neurochir Pol 1999; 33: 693-698.
32. Kasman, L.M., Kasman, A., Westwater, C., Dolan, J., Schmidt, M.G., Norris, J.S. Overcoming the phage replication threshold: A mathematical model with implications for phage therapy. J Virol 2002; 76: 5557-5564.
33. García, P., Martín, A.C., López, R. Bacteriophages of Streptococcus pneumoniae: A molecular approach. Microb Drug Resist 1997; 3: 165-176.